Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00142103
Status:
COMPLETED
Last Update Posted:
2011-05-16
First Post:
2005-08-31
Brief Title:
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus HCV Subjects
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
CPG10101 Combination Therapy For The Treatment Of Hepatitis C A Phase 1b Open Label Randomized Trial Of CPG10101 Alone With Interferon Ribavirin Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus HCV Subjects
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 To characterize the tolerability profile of subcutaneous SC CPG 10101 alone with pegylated interferon ribavirin or both pegylated interferon and ribavirin when administered weekly for twelve weeks in relapsed HCV positive subjects
2 To assess the effect of subcutaneous SC CPG 10101 alone with pegylated interferon ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus HCV RNA concentrations
2 To assess the effect of subcutaneous SC CPG 10101 alone with pegylated interferon ribavirin or both pegylated interferon and ribavirin on serum Hepatitis C Virus HCV RNA concentrations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CPG10101-003 | None | None | None |